BRIEF REPORT

Case Report: Peripartum periventricular leukomalacia resulting in cerebral palsy associated with placenta previa in Japan [version 2; peer review: 1 approved with reservations]

Previously titled: Placenta previa as a risk factor for antenatal- and peripartum periventricular leukomalacia resulting in cerebral palsy in Japan: a retrospective study

Shunji Suzuki

Department of Obstetrics and Gynecology, Japanese Red Cross Katsushika Maternity Hospital, Katsushika-ku, Tokyo, 124-0012, Japan

Abstract

Intrapartum fetal heart rate monitoring abnormalities had been reported to correlate with decreased umbilical artery base excess associated with neonatal seizures. However, we present an infant born at 35 weeks of gestation diagnosed with cerebral palsy associated with periventricular leukomalacia (PVL) without fetal heart rate (FHR) monitoring abnormalities. According to the summary reports of PVL cases published on the home page of the Japan Obstetric Compensation System for Cerebral Palsy (JOCSC), the percentage of placenta previa without FHR monitoring abnormalities in the cases of PVL was 5.7% (12/209), which seemed to be higher than the total percentage of placenta previa reported in Japan (0.3-0.5%).

Keywords

periventricular leukomalacia, placenta previa, Japan

Corresponding author: Shunji Suzuki (czg83542@mopera.ne.jp)

Author roles: Suzuki S: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2020 Suzuki S. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Suzuki S. Case Report: Peripartum periventricular leukomalacia resulting in cerebral palsy associated with placenta previa in Japan [version 2; peer review: 1 approved with reservations] F1000Research 2020, 9:241 https://doi.org/10.12688/f1000research.22878.1

First published: 07 Apr 2020, 9:241 https://doi.org/10.12688/f1000research.22878.1
Introduction
Brain injury in premature infants is generally thought to primarily consist of periventricular leukomalacia (PVL), a distinctive form of cerebral white matter injury. PVL occurs most commonly in premature infants born at less than 32 weeks’ gestation. In an earlier study in Japan, frequent moderate variable deceleration on fetal cardiotocogram (CTG) was observed to be a cause of antenatal PVL in premature infants1. In the report by Ito et al.1, frequent moderate variable decelerations on fetal CTG were observed frequently for infants with antenatal PVL (80.0%) more frequent than control infants (27.3%, p < 0.05). In addition, in low birth weight infants, intrapartum severe variable deceleration or prolonged deceleration have been suggested to play a causal role in PVL2. Although intrapartum fetal heart rate monitoring abnormalities had been reported to correlate with decreased umbilical artery base excess associated with neonatal seizures, recently it has been observed to have no relation to perinatal mortality or pediatric neurologic morbidity3,4. The main factor related to the presence of PVL has been suggested to be gestational age1.

We encountered a case of PVL without fetal heart rate monitoring abnormalities. Subsequently, a review and analysis of the summary reports of PVL cases published on the home page (HP) of the Japan Obstetric Compensation System for Cerebral Palsy (JOCSC) was conducted. We conclude that placenta previa may be a risk factor for antenatal- and peripartum PVL resulting in cerebral palsy (CP) in Japan.

Case report
An elective cesarean section was performed at 35 weeks’ gestation because of placenta previa in the mother with warning bleeding of 60 g. A 2346-g, male infant was delivered with Apgar scores of 8 and 9 at 1 and 5 minutes, respectively. The mother’s pregnancy had progressed uneventfully until the day before the cesarean section. Since 30 weeks’ gestation, she was hospitalized and fetal CTG was monitored every day. There were no moderate/severe decelerations (MSDs) on the CTG. The preoperative fetal CTG, performed 20 minutes before the cesarean section, showed a reassuring fetal status without any fetal heart rate decelerations. The umbilical artery pH was 7.334. The total blood loss during cesarean section was 1,080 g. The infant had no problems during his neonatal period; however, he was diagnosed with CP associated with PVL at the age of 2.

Review and analysis of PVL cases on JOCSC
To re-examine the previous findings in Japan regarding PVL cases4,5, we reviewed the summary reports of antenatal- and peripartum PVL cases published on the HP of the JOCSC launched in 20096. This is a free to access resource, and the cause analysis reports (summary reports) of the patients can be accessed here: http://www.sanka-HP.jqhc.or.jp/documents/analysis/index.html. Those eligible for inclusion in the compensation scheme are infants born between 2009 and 2014 with a birth weight of ≥ 2,000 g, gestation of ≥ 33 weeks and infants born between 2015 and 2019 with a birth weight of ≥ 1,400 g, gestation of ≥ 32 weeks, and severe disability due to CP independent of congenital causes or factors during the neonatal period or later. In the current study, we searched all summary reports published by the end of March 2020 using the keyword ‘PVL’. We have excluded the cases of PVL identified as neonatal cause, such as late circulatory collapse, birth injury, and multiple pregnancies, from the analysis. The following variables were extracted from the reports: fetal heart rate decelerations, intrauterine infection, placental abruption and placenta previa.

Data are presented as number (%). SPSS Statistics software version 20 (IBM Csrorp., Armonk, NY, USA) was used for statistical analyses. For statistical analysis, the X² test was used for the categorical variables between cases with and without fetal heart rate decelerations. Differences with p < 0.05 were considered significant.

Findings
There were 209 cases of PVL published in the HP of JOCSC retrieved in January 2020. In the current examination, 13 cases of monochorionic twins and 9 cases of postnatal PVL due to late circulatory collapse (n = 6), neonatal hypoglycemia (n = 2) and neonatal hyperkalemia (n = 1) were excluded. We examined the presence or absence of MSDs on fetal CTG in the remaining 187 cases. Table 1 shows the clinical characteristics of the 187 cases of antenatal- and peripartum PVL with and without MSDs on fetal CTG. The incidence of neonatal asphyxia in the cases with MSDs was higher than in those without MSDs (p < 0.01); however, the percentage of cases without MSDs was higher than those with MSDs (73.3 vs. 26.7%, p < 0.01). In cases without MSDs, the percentage of neonates born at term was higher than those with MSDs (p = 0.04). These cases might have potentially transient episodes leading to PVL in the uterus between 26 and 32 weeks of gestation. Our case may be same as these cases.

Table 2 shows the perinatal complications in the cases of antenatal- and peripartum PVL with and without MSDs on fetal CTG. The incidence of intrapartum infection and placental abruption in the cases with MSDs was higher than those without MSDs (p < 0.01), while the incidence of placenta previa
Table 1. Clinical characteristics of antenatal- and peripartum periventricular leukomalacia with and without moderate/severe decelerations on fetal cardiotocogram.

<table>
<thead>
<tr>
<th></th>
<th>Moderate/severe decelerations, n (%)</th>
<th>P-value</th>
<th>Odds ratio</th>
<th>95% Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(+)</td>
<td>(-)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>50</td>
<td>137</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gestational age at delivery (weeks)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 30</td>
<td>12 (24.0)</td>
<td>29 (21.2)</td>
<td>0.15</td>
<td>0.471</td>
</tr>
<tr>
<td>30-31</td>
<td>14 (28.0)</td>
<td>26 (19.0)</td>
<td>0.22</td>
<td>0.512</td>
</tr>
<tr>
<td>32-33</td>
<td>15 (30.0)</td>
<td>33 (24.1)</td>
<td>0.46</td>
<td>0.607</td>
</tr>
<tr>
<td>34-36</td>
<td>8 (16.0)</td>
<td>29 (21.2)</td>
<td>Ref.</td>
<td>1</td>
</tr>
<tr>
<td>≥ 37</td>
<td>0 (0)</td>
<td>20 (14.6)</td>
<td>0.04</td>
<td>Inf.</td>
</tr>
<tr>
<td>Cesarean delivery</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>21 (42.0)</td>
<td>52 (38.0)</td>
<td>Ref.</td>
<td>1</td>
</tr>
<tr>
<td>Yes</td>
<td>29 (58.0)</td>
<td>85 (62.0)</td>
<td>0.62</td>
<td>1.19</td>
</tr>
<tr>
<td>Apgar score at 1 min</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 4</td>
<td>22 (44.0)</td>
<td>27 (19.7)</td>
<td>&lt; 0.01</td>
<td>0.223</td>
</tr>
<tr>
<td>4-6</td>
<td>16 (32.0)</td>
<td>44 (32.1)</td>
<td>0.14</td>
<td>0.500</td>
</tr>
<tr>
<td>≥ 7</td>
<td>12 (24.0)</td>
<td>66 (48.2)</td>
<td>Ref.</td>
<td>1</td>
</tr>
<tr>
<td>Urinalysis pH</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≥ 7.0</td>
<td>34 (68.0)</td>
<td>115 (99.1)</td>
<td>Ref.</td>
<td>1</td>
</tr>
<tr>
<td>&lt; 7.0</td>
<td>11 (22.0)</td>
<td>1 (0.9)</td>
<td>&lt; 0.01</td>
<td>0.0270</td>
</tr>
<tr>
<td>Fetal growth restriction</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>No</td>
<td>41 (82.0)</td>
<td>117 (85.4)</td>
<td>Ref.</td>
<td>1</td>
</tr>
<tr>
<td>Yes</td>
<td>9 (18.0)</td>
<td>20 (14.6)</td>
<td>0.65</td>
<td>0.779</td>
</tr>
</tbody>
</table>

Table 2. Perinatal complications in the cases of antenatal- and peripartum periventricular leukomalacia with and without moderate/severe decelerations on fetal cardiotocogram.

<table>
<thead>
<tr>
<th></th>
<th>Moderate/severe decelerations, n (%)</th>
<th>P-value</th>
<th>Odds ratio</th>
<th>95% Confidence Interval</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(+)</td>
<td>(-)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>50</td>
<td>137</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Perinatal complications</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intrauterine infection</td>
<td>19 (38.0)</td>
<td>22 (16.1)</td>
<td>&lt; 0.01</td>
<td>0.312</td>
</tr>
<tr>
<td>Placental abruption</td>
<td>8 (16.0)</td>
<td>3 (12.2)</td>
<td>&lt; 0.01</td>
<td>0.118</td>
</tr>
<tr>
<td>Placenta previa</td>
<td>0 (0)</td>
<td>12 (8.8)</td>
<td>0.04</td>
<td>Inf.</td>
</tr>
</tbody>
</table>

in the cases without MSDs was higher than those with MSDs (p = 0.04). The former results were as expected, while the latter may be a new finding. The percentage of placenta previa in the cases of PVL was 5.7% (12/209), which seemed to be higher than the total percentage of placenta previa reported in Japan (0.3-0.5%).
Discussion
We present a case of placenta previa without MSDs on fetal CTG resulted in cerebral palsy due to PVL. To date, some possible mechanisms leading to PVL in cases of placenta previa has been discussed in Japan. Oda et al. reported that the main risk factor for PVL in preterm placenta previa is an initial antepartum hemorrhage <28 weeks of gestation and they speculated that decreased placental perfusion in the second trimester of pregnancy is associated with the developmental window of vulnerability for PVL. However, Furuta et al. observed that acute and massive bleeding from placenta previa at around 30 weeks of gestation is a risk factor for PVL and CP requiring careful neonatal follow-up. However, in the 12 cases of placenta previa in that study, massive bleeding and initial bleeding < 28 weeks of gestation were observed in only 4 (33.3%) and 1 cases (8.3%) Kmauzaki et al. observed that gross lesions with disturbance of uteroplacental circulation including massive retroplacental hematoma, extensive infarction or thrombosis, and marked basal or perivillous fibrin deposition frequently in placentae in cases of antenatal- and peripartum PVL. They also observed the high frequency of ischemic changes in villi in those placentae. The same findings have been reported to be observed in cases of placenta previa. The same findings may have occurred in our case.

Based on the data from JOCSC, serious abnormal fetal heart rate patterns were not observed in approximately 70% of cases with antenatal- and peripartum PVL on fetal CTG, and placenta previa itself may be associated with the development of antenatal- and/or peripartum PVL. A further study of PVL with controls may be needed.

Data availability
Underlying data
The Japan Obstetric Compensation System for Cerebral Palsy (JOCSC) for is a free to access resource. Cause analysis reports (summary reports) for patients with periventricular leukomalacia can be accessed here: http://www.sanka-hp.jcqhc.or.jp/documents/analysis/index.html, Feb 12, 2020). These reports are in Japanese.


This project contains the following underlying data:


Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).

Consent
Written informed consent for publication of the clinical details of the case report was obtained from the mother in the case report.

References
Ambrogio Pietro Londero  
Clinic of Obstetrics and Gynecology, DAME, ASUI - Presidio Ospedaliero Universitario "SM della Misericordia", University of Udine, Udine, Italy

I read the article by Suzuki S entitled: "Placenta previa as a risk factor for antenatal- and peripartum periventricular leukomalacia resulting in cerebral palsy in Japan: a retrospective study" with interest.

The argument is very interesting but I have some points to highlight in order to improve the manuscript itself:

**Major issues:**

1. The abstract does not reflect in a proper manner the content of the manuscript. In particular, the conclusion in the abstract is a clear overstatement. In fact, the data analyzed in the manuscript do not allow any kind of conclusion about a correlation between placenta previa and neonatal periventricular leukomalacia. In the dataset, only cases of neonatal periventricular leukomalacia without controls are present.

2. For the same reason, the title of the article is also not appropriate, and also the manuscript's main-text itself should be fixed.

3. For the clinical case report, I suggest following the CARE guidelines.

**Minor issues:**

1. A minor issue is that the clarity of the whole manuscript would benefit from a revision of the English language.

**Is the work clearly and accurately presented and does it cite the current literature?**
Partly

**Is the study design appropriate and is the work technically sound?**
Partly
Are sufficient details of methods and analysis provided to allow replication by others?
Yes

If applicable, is the statistical analysis and its interpretation appropriate?
Partly

Are all the source data underlying the results available to ensure full reproducibility?
Yes

Are the conclusions drawn adequately supported by the results?
No

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 27 Apr 2020

Shunji Suzuki, Japanese Red Cross Katsushika Maternity Hospital, Katsushika-ku, Japan

Thank you very much for the comments and critique of my manuscript. I have been able to respond positively to each suggestion and we believe the paper has been strengthened. The changes are highlighted with red color.

I have re-written the abstract, case report and the title according to your suggestions. In addition, my English has been edited.

Thank you very much for your suggestions, again.

I do hope and trust that with these changes the manuscript is now acceptable for publication.

Thank you for considering my paper.

Sincerely yours,

Shunji Suzuki, MD
Department of Obstetrics and Gynecology,
Japanese Red Cross Katsushika Maternity Hospital
5-11-12-2 Tateishi, Katsushika-ku, Tokyo 124-0012 Japan
Tel: +81-3-3693-5211
Fax: +81-3-3694-8725
e-mail: czg83542@mopera.ne.jp

Competing Interests: There are no competing interests.
The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com